Phase II trial of single-agent oral vinorelbine in elderly (≥70 years) patients with advanced non-small-cell lung cancer and poor performance status

Annals of Oncology

Volumn 21, Issue 6, 2009, Pages 1290-1295

  Camerini, A ^a   Valsuani, C ^a   Mazzoni, F ^b   Siclari, O ^a   Puccetti, C ^a   Donati, S ^a   Rondini, M ^a   Tartarelli, G ^a   Puccinelli, P ^a   di Costanzo, F ^b   Amoroso, D ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Elderly; Non small cell lung cancer; Vinorelbine

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; GEMCITABINE; NAVELBINE; ANTINEOPLASTIC AGENT; VINBLASTINE;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL STATUS; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; DAILY LIFE ACTIVITY; DISEASE COURSE; HEALTH STATUS; LUNG NEOPLASMS; MORTALITY; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; SURVIVAL; TASK PERFORMANCE; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; MALE; PALLIATIVE CARE; SURVIVAL ANALYSIS; TASK PERFORMANCE AND ANALYSIS; VINBLASTINE;

EID: 77953984760     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp525     Document Type: Article

References (35)

1. Ries LAG, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review 1975-2000. Bethesda, MD: National Cancer Institute 2003.
2. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
3. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
4. Gridelli C, Perrone F, Gallo C et al.; Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
5. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Populationbased study of 20 651 cases. Ann Oncol 2002; 13: 1087-1093.
6. Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 2002; 20 (18 Suppl): 23S-33S.
7. Repetto L, Balducci L. A case for geriatric oncology. Lancet Oncol 2002; 3: 289-297.
8. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20: 494-502.
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
10. Katz S, Ford AB, Moskowitz RW et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963; 185: 914-919.
11. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-186.
12. Greil R, Thodtman R, Roila F. on the behalf of the ESMO Guidelines Working Group. Erythropoietins in cancer patients: ESMO recommendations for use. Ann Oncol 2008; 19 (Suppl 2): ii113-ii115.
13. Gridelli C, Maione P, Rossi A et al. Chemotherapy of advanced NSCLC in special patient population. Ann Oncol 2006; 17 (Suppl 5): v72-v78.
14. Gridelli C, Maione P, Rossi A et al. Management of unfit older patients with advanced NSCLC. Cancer Treat Rev 2009; 35: 517-521.
15. Albain KS, Crowley JJ, LeBlanc M et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-1626.
16. Takigawa N, Segawa Y, Okahara M et al. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 1996; 15: 67-77.
17. Lilenbaum RC, Herndon JE, List MA et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B study 9730. J Clin Oncol 2005; 23: 190-196.
18. Gridelli C, Ardizzoni A, Le Chevalier T et al. Treatment of advanced non-smallcell lung cancer patients with ECOG performance status 2: results of a European Experts panel. Ann Oncol 2004; 15: 419-426.
19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
20. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
21. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354-2362.
22. Hanna N, Shepherd FA, Fossella VF et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
23. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001; 6 (Suppl 1): 4-7.
24. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
25. Borner MM, Schoffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-358.
26. Coates A, Dillenbeck CF, McNeil DR et al. On the receiving end II: linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol 1983; 19: 1633-1637.
27. Griffin AM, Butow PN, Coates AS et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7: 189-195.
28. Baka S, Ashcroft L, Anderson H et al. Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status ≤70) and advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 2136-2144.
29. Blakely LJ, Schwartzberg L, Keaton M et al. A phase II trial of pemetrexed and gemcitabine as first-line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2009; 66: 97-102.
30. Gralla RJ, Gatzemeier U, Gebbia V et al. Oral vinorelbine in the treatment of nonsmall cell lung cancer: rationale and implications for patient management. Drugs 2007; 67: 1403-1410.
31. Gridelli C, Manegold C, Mali P et al. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur J Cancer 2004; 40: 2424-2431.
32. Kanard A, Jatoi A, Castillo R et al. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer 2004; 43: 345-353.
33. Parente B, Queiroga H, Espanhol V et al. Single-agent oral vinorelbine as chemotherapy in elderly patients with advanced stage or metastatic non-small cell lung cancer. In 11th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer 2005; abstract book; (Abstr 70).
34. Mendez M, Andrade J, Esquero G et al. Oral vinorelbine as single-agent first-line treatment in elderly patients with advanced non-small-cell lung cancer. Eur J Cancer 2007; 5 (Suppl 4): (Abstr 6605).
35. Tomirotti M, Galassi B. Oral vinorelbine in first-line treatment of NSCLC in elderly: updated results of a low dose schedule in a single institution experience. J Clin Oncol 2007; 18 (Suppl 25): (Abstr 18192).